![World cancer day](https://robbinsllp.com/wp-content/uploads/2023/01/world-cancer-day-300x200.jpg)
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate
Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate
Latch, Inc. (LTCH) f/k/a TS Innovation Acquisitions Corp. (TSIA) Issued a False and Misleading Registration Statement in Connection with its Merger
The SEC is Making Changes in 2023
Enovix Corporation (ENVX) Misled Investors Regarding its Ability for Production and Profitability
Robbins LLP is Investigating the Acquisition of ForgeRock, Inc. by Thoma Bravo
BioLineRx Ltd. (BLRX) Misrepresented its Financial Fortitude and Ability to Bring its Drug to Market
Avaya Holdings Corp. (AVYA) Failed to Disclose Deficient Internal Control Over Financial Reporting
Gaotu Techedu, Inc. (GOTU) Failed to Disclose the Impact of China’s Ban on For-Profit Tutoring on Its Business Prospects
Daktronics, Inc. (DAKT) Unable to Timely File SEC Reports and Questions its Ability to Continue as a Going Concern
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.